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E-mail: rick.wansink@radboudumc.nlMyotonic dystrophy type 1 (DM1) is caused by (CTG,CAG)n-
repeat expansion within the DMPK gene and thought to be
mediated by a toxic RNA gain of function. Current attempts
to develop therapy for this disease mainly aim at destroying
or blocking abnormal properties of mutant DMPK (CUG)n
RNA. Here, we explored a DNA-directed strategy and demon-
strate that single clustered regularly interspaced short palin-
dromic repeats (CRISPR)/Cas9-cleavage in either its 50 or 30
unique ﬂank promotes uncontrollable deletion of large seg-
ments from the expanded trinucleotide repeat, rather than
formation of short indels usually seen after double-strand
break repair. Complete and precise excision of the repeat tract
from normal and large expanded DMPK alleles in myoblasts
from unaffected individuals, DM1 patients, and a DM1
mouse model could be achieved at high frequency by dual
CRISPR/Cas9-cleavage at either side of the (CTG,CAG)n
sequence. Importantly, removal of the repeat appeared to
have no detrimental effects on the expression of genes in
the DM1 locus. Moreover, myogenic capacity, nucleocytoplas-
mic distribution, and abnormal RNP-binding behavior of
transcripts from the edited DMPK gene were normalized.
Dual sgRNA-guided excision of the (CTG,CAG)n tract by
CRISPR/Cas9 technology is applicable for developing isogenic
cell lines for research and may provide new therapeutic op-
portunities for patients with DM1.
INTRODUCTION
Myotonic dystrophy type 1 (DM1) is an inherited multisystemic
disorder that manifests itself at different ages, with variable
expression of progressive skeletal muscle wasting, myotonia,
dysfunction of the heart, gastrointestinal problems, insulin resis-
tance, cataract, and alterations in cognitive functions and behavior
associated with white matter loss in the central nervous system.1,2
DM1’s autosomal-dominant character, complex symptoms, and
progression are caused by expansion of a (CTG,CAG)n-triplet
repeat located in the 30 UTR of the DMPK gene3–5 and in a24 Molecular Therapy Vol. 25 No 1 January 2017 ª 2017 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://partially overlapping antisense (DM1-AS) gene.6,7 In DM1 fam-
ilies, the repeat contains more than 37 to up to several thousands
of triplets and is unstable, both somatically8,9 and intergeneration-
ally,10–12 with a bias toward expansion, causing an increase in
severity and an earlier onset of disease symptoms during aging
and over successive generations.
Several mechanisms may contribute to the molecular pathogenesis
of DM1, but the prevailing idea is that expanded (CUG)n-con-
taining DMPK transcripts are dominant in disease etiology. In
cells where the gene is expressed, expanded DMPK transcripts
may abnormally associate with RNA-binding proteins, like mem-
bers of the muscleblind-like (MBNL1–3), DEAD-box helicase
(DDX), and heterogeneous ribonucleoprotein particle (hnRNP)
families, causing sequestration in ribonucleoprotein (RNP) com-
plexes that occur as distinct foci or remain in a diffuse soluble
state. Other anomalies in the ribonucleoprotein network of DM1
cells are caused by altered phosphorylation of RNA-binding pro-
teins like CELF1 or Staufen 1,13,14 triggered by kinase activation
in stress responses. In turn, these imbalances have serious in trans
consequences for faithful alternative splicing,15,16 polyadenyla-
tion,17 and expression of miRNAs,18–20 creating a network of
cellular dysfunction. Additional problems may emerge from the
production of toxic homopolymeric polypeptides, which are
formed by decoding of the normally untranslated (CUG)n repeat
tract in DMPK mRNA by repeat-associated non-ATG (RAN)creativecommons.org/licenses/by-nc-nd/4.0/).
www.moleculartherapy.orgtranslation.21,22 Similar toxic mechanisms may be active in tissues
that express DM1-AS transcripts with expanded (CAG)n repeats.
Finally, (CTG,CAG)n expansion may also modify nearby chro-
matin structure,23 which is associated with epigenetic marking or
altered expression of other genes in the DM1 locus like the SIX5
gene.23–28
Due to this enormous complexity and our still unripe knowledge
about the signiﬁcance of these pathobiological mechanisms, it is
not surprising that the development of therapy that could stop the
cellular problems and thereby delay the onset or slow the progres-
sion of muscle wasting, white matter loss in brain, and other disease
features seen in DM1 patients is still an unmet medical goal. From
DM1 cell and mouse model studies, there is signiﬁcant support for
considering the RNA gain-of-function toxicity the prime therapeutic
target, and proof-of-concept testing has already demonstrated that
antisense oligonucleotide (AON)-mediated degradation of DMPK
(CUG)n transcripts or disruption of abnormal RNP complexes by
RNA binding or MBNL displacement has potential therapeutic util-
ity.29–32 Hurdles that still have to be overcome for use in vivo relate
to modes of administration, cell-type speciﬁcity of action, and
possible immune effects of repeated treatment with AONs or small
molecule drugs. Also, more fundamental questions about repeat
length effects on DMPK mRNA structure and accessibility in
abnormal RNP complexes, AON, or drug effects on intracellular
(re)distribution of repeat-containing RNAs and their involvement
in RAN translation need attention for further progress. Moreover,
therapies that degrade the (CUG)n transcript or destabilize ribonu-
clear foci are expected to have no impact on the modiﬁcation of
local chromatin structure, the dysregulation of DM1-AS transcripts,6
or SIX524,25,33 and possibly other in cis pathobiological effects at the
DNA level.
Here, we have started to evaluate the use of somatic gene editing with
endonucleases as a promising alternative for the correction of DM1
problems because this strategy offers the opportunity to drive per-
manent correction of the (CTG,CAG)n expansion mutation and
cancel out DM1-associated problems at all levels, including the cis
epigenetic effects and trans effects on the transcriptome and prote-
ome.34 Speciﬁcally, we have sought to test in muscle cells whether
the clustered regularly interspaced short palindromic repeats
(CRISPR)/Cas9 system can be used to excise the expanded
(CTG,CAG)n repeat and negate its negative effects by normaliza-
tion of the expression and nucleocytoplasmic transport of long
(CUG)n RNA from the mutant DMPK allele, without compromising
the expression of genes like SIX5 and DM1-AS. By conducting tests
in myoblasts from a transgenic DM1 mouse model, DM1 patients,
and unaffected individuals, we analyzed how the abnormal topology
of the repeat affects the efﬁcacy of cleavage and repair of double-
strand DNA breaks (DSBs) and gaps introduced in the DM1 locus
by single and dual CRISPR/Cas9 genome editing approaches. Our
ﬁndings on the gene editing outcome are applicable in the develop-
ment of isogenic cell lines for research and in developing new stra-
tegies for future therapeutic intervention options in the tissues ofpatients with myotonic dystrophy and perhaps other types of repeat
expansion disorders.
RESULTS AND DISCUSSION
CRISPR/Cas9 Genome Editing in the DM1 Locus
To select target sequences for CRISPR/Cas9 nucleases in the 30 UTR
in DMPK exon 15, we used different versions of guide RNA (gRNA)
design software, allowing prediction of performance in the context of
a human genomic background. Multiple candidate target sequences
with low probability for off-target recognition and a high capacity
for promoting double-stranded DNA (dsDNA) cleavage at unique
sequence sites upstream and downstream of the (CTG,CAG)n repeat
were identiﬁed (Figure 1A). The repeat tract itself cannot be targeted
internally because of the absence of a protospacer adjacent motif
(PAM) sequence. Sequences at its periphery were poor targets (yellow
arrows in Figure 1A) because prediction indicated a high probability
of targeting to other (CTG,CAG)n repeats elsewhere in the genome.
Moreover, pilot experiments revealed a conspicuous low efﬁciency for
CRISPR/Cas9 nucleases with repeat-directed gRNAs, so they were
not considered further (Table S1; CRISPR-5 and -7 and data not
shown).
For comparison of the efﬁcacy of various CRISPR/Cas9 nuclease-
gRNA expression plasmid combinations, we chose to work with mus-
cle cells, a cell type that is highly relevant for DM1 manifestation.
Immortalized myoblast lines from unaffected individuals (LHCN
and KM155C25),35 lineages that have overcome replicative aging
because of retroviral expression of hTERT and CDK4,35 were em-
ployed. LHCN myoblasts carry two identical DMPK alleles with a
(CTG,CAG)5 repeat, which facilitated analysis of efﬁciency of
CRISPR/Cas9-mediated DSB formation by circumventing the need
for discrimination between allelic repeat-speciﬁc effects on indel for-
mation after break repair. Cleavage efﬁciency in nucleofector-trans-
fected cells was assessed by a T7 endonuclease I (T7EI) assay36 on
genomic DNA from pools of these cells (Figure 2B). As controls in
the assay, untreated LHCN myoblasts showed a single, distinct
T7 endonuclease-resistant fragment, whereas for KM155C25 myo-
blasts, carrying one (CTG,CAG)5 and one (CTG,CAG)14 allele,
cleavage across CTG5,CAG14 or CTG14,CAG5 misaligned tracts
in hybrid PCR products resulted in the appearance of two additional
fragments (Figures 2A and 2B). Based on signal strength in the T7EI
assay, two gRNA/Cas9 nucleases that showed the best ability to direct
cleavage were chosen, with target sites located 11 bp upstream of the
ﬁrst CTG triplet (CRISPR-2, 8%–21% efﬁciency) and 51 bp down-
stream of the last CTG triplet (CRISPR-3, 14% efﬁciency). Other
gRNA vectors with lower efﬁciencies (e.g., CRISPR-1 or candidates
in Figure 1A; Table S1) were not used further in this study.
As a next step, we assessed activity of CRISPR-2 and -3 nucleases
toward potential off-target sites elsewhere in the genome. By use
of computational target prediction, potential sites were identiﬁed
on the basis of similarity to the gRNA sequences. Among the
sites with the highest prediction values were the CARMIL2,
EBF3, DVL1, and ALK loci (Table S2). Veriﬁcation with theMolecular Therapy Vol. 25 No 1 January 2017 25
Figure 1. CRISPR Design
(A) Schematic overview of CRISPR/Cas9 target sites across part of the 30 UTR in DMPK exon 15. The (CTG,CAG)n repeat is indicated in black, and flanking regions in the
DMPK gene are in gray. Using different web tools, multiple candidate gRNA target sequences were identified upstream and downstream of the repeat. Positions of guide
RNA target sites are displayed by arrows in different colors, representing a good (red), average (blue), or poor (yellow) utility score. Target sites that were chosen for further
experiments are encircled and numbered as CRISPR-1, CRISPR-2, etc., in the text. (B) Schematic overview of the structural organization of the DMPK gene, including the
(CTG)n repeat in exon 15 in black. Positions of cleavage sites for CRISPR-1, -2, and -3, i.e., the gRNA target sites that were most intensely used in this study, are indicated.
The corresponding sequence in exon 15 is displayed below, with the (CTG)n repeat in bold black, CRISPR sites in red, and PAM sequences in green letters.
Molecular TherapyT7E1 assay revealed no indels within these loci, indicating that
no or very low cleavage activity outside the DMPK locus occurred
upon use of CRISPR-2 and -3 (Figure S1). We realize, however,
that indel formation at these and non-predicted off-target cleav-
age sites in the genome may depend on the timing and level of
expression and the cell type in which these CRISPRs are being
used. Precise monitoring of their ﬁdelity and speciﬁcity would
require whole genome sequencing for every variable, which is
not realistic at this point. Of note, while this work was in prog-
ress, development of a new high-ﬁdelity version of CRISPR/Cas9
nuclease was reported.37 Switching to this new tool, in combina-
tion with the two gRNAs identiﬁed here, may thus become a use-
ful strategy for the avoidance of potential problems. Because our
observations made it sufﬁciently clear that the occurrence of off-
target DSBs constitutes only a minor problem with gene editing
in the DMPK gene in myoblasts, we decided not to pursue this
issue further here.26 Molecular Therapy Vol. 25 No 1 January 2017Deletion of a Short (CTG)n Repeat in Unaffected Human
Myoblasts
Having observed that CRISPR-2 and -3 were effective tools for cleav-
age in the 30 UTR of the DMPK gene, we next wondered whether
combined use could be applied for removal of the entire repeat-con-
taining segment. This strategy was ﬁrst tested in (CTG)5/(CTG)5
LHCN myoblasts, in which this segment has the smallest possible
size, spanning only 77 bp. T7E1 analysis of editing events (Figure 2C)
combined with conventional PCR analysis (Figure 2D) revealed the
appropriate size changes across the genomic area. Importantly, in
most cases in which cleavage had occurred, both CRISPR-2 and -3
must have been simultaneously active on one allele. PCR ampliﬁca-
tion gave the original and edited products of 636 and 559 bp, respec-
tively, in a 5:1 ratio (Figure 2D). This conﬁrmed that the 77-bp
repeat-containing segment had been deleted in a fair percentage of
cells and also that the area was unmodiﬁed in other cells within
the population.
Figure 2. CRISPR Activity in Myoblasts with Normal-
Size (CTG,CAG)n Repeats
(A) Schematic outline of the T7EI assay for determination
of CRISPR cleavage efficiency. Part of DMPK exon 15
([CTG,CAG]n repeat in black) containing CRISPR-1, -2,
and -3 recognition sites and positioning of PCR primers
used for amplification of the relevant segment are shown
on top. Possible fragments formed in the assay are de-
picted, with sizes given underneath. (B) T7EI assay of DNA
from small pools of transfection-positive LHCN cells.
Quantification of signal strength (assessed by scanning of
fluoresce signal intensity upon UV illumination for all assays
shown in B–E) revealed target efficiencies of <1% for
CRISPR-1, 8%–21% for CRISPR-2, and 14% for
CRISPR-3. DNAs of non-transfected (untr.) LHCN (two
alleles with equal DMPK repeat lengths) and KM155C25
myoblasts (one [CTG,CAG]5 and one [CTG,CAG]14
allele) were used as negative and positive control,
respectively. (C) T7E1 assay of DNA from a pool of LHCN
myoblasts treated with CRISPR-2 and -3 simultaneously.
Untransfected LHCN and KM155C25 were included as
controls. Note that we could not differentiate between
deletion of the entire region between the two CRISPR sites
or simultaneous formation of small indels at each of
the two CRISPR sites. (D) PCR analysis of the relevant
DMPK genomic segment after dual genome-editing with
CRISPR-2 and -3. The upper band represents the un-
modified PCR product. The lower band is indicative for
deletion of the 77 bp (CTG,CAG)5 repeat and flanking
regions in a small portion of CRISPR-2- and CRISPR-3-
treated cells. (E) PCR analysis of genome changes in three
CRISPR-2- and CRISPR-3-treated LHCN cell clones.
Clone LHCN-B2.1 contains two unmodified repeats (sin-
gle signal at 636 bp), whereas clone LHCN-B2.2 has a
repeat deletion on both alleles (single signal at 559 bp).
Clone LHCN-F3.2 carries one unmodified and one edited
allele (signals at 559 bp and 636 bp). (F) Sequence verifi-
cation of excision of the repeat-containing segment. Top:
sequencing profile of the DMPK exon-15 gene region in
clonally expanded LHCN cells after dual gene editing with
CRISPR-2 and -3. The site at which the DSBs are fused is
indicated by an arrowhead. No indels were found. Bottom:
the exon-15 sequence lacking the 77-bp repeat-contain-
ing segment aligned with the normal DMPK sequence.
www.moleculartherapy.orgConventional PCR analysis of a series of 18 single-cell clones (repre-
sentative clones shown in Figure 2E), obtained by limiting dilution af-
ter initial enrichment in small cell pools, showed that in67% of cells,
the (CTG,CAG)5-containing segment had been completely removed
from at least one allele. Sequence analysis of PCR products conﬁrmed
that this excision had largely occurred cleanly, without additional
deletions or insertions in 83% of the modiﬁed target sites (Figure 2F;
Table S3). LHCN cell clones with double clean deletions were desig-
nated LHCN-(clone#)-D/D cells (Table S4) and used for later biolog-
ical typing (see below). Only in 17% of alleles, small 2–27 nt indels
(deletions only) were identiﬁed at CRISPR-2 and/or -3 recognition
sites. Among the cells with these changes, small deletions were slightly
more frequent at the CRISPR-3 site, presumably because of better
guidance efﬁciency associated with more frequent cleavage.Removal of a Long (CTG,CAG)n Repeat Segment in Myoblasts
Derived from a DM1 Mouse Model
To characterize the editing potential of the CRISPR-2/-3 nuclease
combination for DMPK genes with large (CTG,CAG)n expansions,
we performed an initial series of tests in DM500 myoblasts, an
immortalized cell lineage derived from the calf muscle of a com-
pound-hemizygous DM1model mouse that carried one cosmid-sized
transgenic insert with expanded (CTG,CAG)330 DMPK allele38 and
one H-2Kb-SV40tsA58 transgene.31 We reasoned that the best view
on authentic genome and transcript changes after dual CRISPR cleav-
age would be obtained in cells with only one target chromosome,
without the possibility of target competition or gene conversion be-
tween DMPK alleles of different lengths, as might occur in patient
cells with two chromosomes 19. Unfortunately, this criterion wasMolecular Therapy Vol. 25 No 1 January 2017 27
Molecular Therapynot fully met because the DM500 myoblast lineage had undergone
tetraploidization during propagation in culture at the permissive tem-
perature (Figure S2), a common feature of cells that express the SV40
large T antigen during cell cycle progression.39,40 Small-pool PCR
analysis of repeat length variation in the DM500 cell population re-
vealed three types of main alleles with 540, 570, and 610
CTG,CAG repeats (Figures 3A–3D) and a subset of rarer expansion
and contraction events around these two alleles. We assume that the
three main alleles detected represent somatic variants that arose early
after, or possibly during, the tetraploidization event. Overall, the de-
gree of somatic instability in the DM500 cell population appeared
relatively low, likely reﬂecting the comparatively low level of somatic
instability observed in muscle in vivo in the original transgenic mice38
and the close correlation between the tissue speciﬁcity of somatic
mosaicism in vivo and that observed in vitro in tissue culture.41
Although the presence of two chromosomes per cell containing large
expanded alleles does not reﬂect the normal situation in patients, we
nonetheless considered this cell line useful for determining the efﬁ-
ciency of CRISPR-mediated cutting in modifying the length of large
expanded (CTG,CAG)n repeats at the DM1 locus.
Encouragingly, small-pool PCR analysis of the entire population of
quadruple-transfected cells (CRISPR-2 and -3 gRNAs, Cas9 vector,
and EGFP-reporter plasmid) suggested the 1.7-kbp deletions
(540/570/610 CTG,CAG triplets plus 62 bp of ﬂanking sequences)
were very efﬁcient, yielding a predominant product of200 bp when
ampliﬁed with the distal DM-A/-BR primer pair (Figures 3A and 3C).
Although the primary product appeared to be the hoped for clean
excision of the repeat tract, a subset of molecules with CRISPR-2
and -3 treatment yielded variably sized fragments, presumably
carrying repeat tracts intermediate between (CTG,CAG)0 and
(CTG,CAG)500 (Figure 3B). The failure to detect most of these prod-
ucts with the inner DM-C/-DR primer pair (Figure 3B) suggests that
many of these targeted loci acquired deletions that have removed the
DM-C or DM-DR primer site (note the clean full-excision DM-C/
DM-DR product is only 85 bp long and is not expected to be detected
with the DM56 probe).
Interestingly, the small-pool PCR analysis revealed that both
CRISPR-2 and -3, singly and together, preferentially targeted the
(CTG,CAG)570 and (CTG,CAG)610 repeat tracts (Figures 3C and
3D). We assume that the chromatin conﬁguration at the two trans-
genic DM1 loci differed between the duplicated chromosomes and
that this generated differential accessibility for CRISPR/Cas9 com-
plexes, consistent with recent data suggesting a role for chromatin
structure in mediating CRISPR activity.42,43 This may have important
implications for the targeting efﬁciency of the normal and mutant
chromosome in DM1 patient cells, given the known effect of the
(CTG,CAG)n repeat expansion in altering the local chromatin
structure.23,27,33
To better deﬁne the efﬁcacy of CRISPR-mediated removal of large
genomic regions, we also performed PCR (Figure 3E) and sequence
analysis of the DMPK exon 15 region on a number of individually28 Molecular Therapy Vol. 25 No 1 January 2017propagated genome-edited DM500 cell clones. From this analysis,
we estimated that clean loss of the segment between the CRISPR-2
and -3 cleavage sites had occurred in approximately one-third
(30%) of the modiﬁed transgenic chromosomes (Table S3). Imperfect
deletions extending beyond the CRISPR sites were seen in 4% of the
modiﬁed transgenic chromosomes. Other mutations (7%) involved
large insertions and deletions and inversions. A representative subset
of clones with clean repeat loss, i.e., with complete deletion in either
one or both of the identical transgenic chromosomes (designated
DM500-[clone#]-D1 or DM500-[clone#]-D2, respectively; Table S4),
was used for further biological study (detailed below). In a number
of clones that still contained at least one transgenic chromosome
with an expanded (CTG,CAG)540/570/610 repeat, small indels of
1–24 bp were found at the CRISPR-2 or -3 recognition sites. These
indels were present in 37% of all modiﬁed transgenic chromosomes,
which is higher than the percentage of indels found in CRISPR-edited
LHCN cells (17%; Table S3). About 90% of the indels consisted of
small deletions, and 10% consisted of small insertions (data not
shown). This ﬁnding may reﬂect species (i.e., human versus mouse),
chromosome, or cell-type-speciﬁc differences in efﬁcacy or modes of
DNA repair. Also, cis effects of the long (CTG,CAG)540/570/610
repeat on the repair ability of CRISPR-2 or -3 breaks may have
been involved. DSBs stimulate DNA repair by at least two distinct
mechanisms—non-homologous end joining (NHEJ) and homol-
ogy-directed repair (HDR)—of which the former is error prone.44
Differential activities of NHEJ or HDR on any of the two chromo-
somes 19 of different parental origin in the LHCN cells or on the
two essentially identical transgenic chromosomes of maternal origin
in DM500 cells or simply timing differences needed for sealing of
small 77-bp or large 1.7-kbp gaps by these mechanisms may thus
have inﬂuenced the steps used for sealing of the CRISPR cut sites
by DNA-repair enzymes.
Single DSBs Near a Long (CTG,CAG)n Segment Frequently
Induce Loss of the Entire Repeat
In order to gain further insight into the mechanism(s) that direct
healing of the large gap between CRISPR-2- and CRISPR-3-induced
DSBs in DM500 myoblasts, we examined the fate of the repeat
segment after a single cleavage upstream or downstream by either
CRISPR-2 or -3, respectively. Triple transfection (gRNA vector,
Cas9 vector, and EGFP reporter), followed by cell sorting for GFP,
was therefore executed. For global monitoring of sequence alterations
within the target region, we PCR ampliﬁed genomic DNA isolated
from small batches of 20–30 individual clones, propagated until day
28 after transfection, and combined this with detection by Southern
blot analysis. To cover a broad range of possible indels, a large region
was PCR ampliﬁed, bracketing the entire repeat and 273 bp and
348 bp of unique sequences upstream and downstream of the repeat,
including CRISPR-2 and -3 sites. PCR products were hybridized with
two independent probes (Figure 4). Even though segments with long
repeats ampliﬁed with poor efﬁciency, these analyses were informa-
tive and demonstrated that introduction of one DSB at either side
induced loss of almost the entire repeat surprisingly often, occurring
once or multiple times in almost every batch of pooled cells (Figure 4).
Figure 3. Treatment of DM500 Cells with CRISPR-2 and/or -3
(A) Schematic overview of CRISPR/Cas9 target sites relative to the (CTG,CAG)n repeat (black) and the flanking DNA (gray) PCR primers (arrows) and probes used for small
pool PCR analysis. (B–D) Small-pool PCR analysis of genomic DNA from DM500 cells treated with CRISPR-2 and/or CRISPR-3. (B) shows amplicons from control and
treated DM500 cells, generated using the inner primers (DM-C/DR) and hybridized using the (CTG,CAG)n probe DM56. (C) shows amplicons from control and treated
cells, generated using the outer primers (DM-A/-BR) and hybridized using the 50-flanking probe. For the untreated and treated cells, four replicate PCRs containing 50
molecules of template DNA are shown. Note that a clean full-excision DM-C/-DR product is only 85 bp long and is not expected to be detected with the DM56 probe in (B). In
(B) and (C), the molecular weight markers (right-hand scale) have been converted to the number of (CTG,CAG)n repeats on the left-hand scale. (D) A zoomed-in shorter
exposure of the autoradiograph in (B) reveals that the DM500 cell line comprises three primary alleles of540,570, and610 (CTG,CAG)n repeats and that the570 and
610 alleles are preferentially modified by both CRISPR-2 and -3. (E) PCR analysis of genome changes in DM500 clones treated with CRISPR-2 and -3 using the DMPK e15
primers described in Materials and Methods. Clone DM500-A2.6 contains unmodified (CTG,CAG)540/570/610 repeats (single signal at 2.2 kb). Clone DM500-A1.3-D2
has a repeat deletion on both chromosome copies (single signal at 559 bp). Clone DM500-A2.2-D1 carries one unmodified allele and one edited allele (signals at2.2 kb and
559 bp, respectively). Note that the enormous difference in signal intensity is due to relative inefficient amplification of the expanded repeat-containing allele.
www.moleculartherapy.org
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Figure 4. Alterations in the DM500 Repeat Region
after Cleavage with a Single CRISPR
DM500 cells were treated with either CRISPR-2 or -3,
after which a 2.2-kb region (including the (CTG,CAG)530/
580 repeat) was PCR amplified and subsequently
analyzed on blot using 32P-labeled probes. (A) Top: outline
of the relevant region in DMPK exon 15. Shown are the
(CTG,CAG)500 repeat in black, cleavage sites for
CRISPR-2 and -3, and locations of PCR primers (arrows)
and probes used for hybridization detection (bars). Bot-
tom: four large panels showing signals from PCRproducts
from nine pools of DM500 cells (20–30 clones per pool)
treated with CRISPR-2 (left panel) or CRISPR-3 (right
panel), hybridized with probe 1, a 32P-labeled DMPK
oligonucleotide located 50 of the CRISPR cleavage sites
(upper panels), or probe 2, a 32P-labeled (CAG)9 oligo-
nucleotide (lower panels). Besides, PCR products of un-
treated DM500 cells and clone DM500-A1.3-D2 carrying a
verified deletion of both repeats were used as controls
(small panels on far right). Presence of small PCR prod-
ucts in the upper panels indicates deletion of large parts of
the repeat in a fair proportion of cells. These products are
invisible in the lower panels because the (CAG)9 probe will
not bind if the repeat is entirely lost or considerably
shortened. (B) Overview of different types of deletions
induced by cleavage with single CRISPRs in isolated
DM500 cell clones treated with CRISPR-2 (left; four ex-
amples) or CRISPR-3 (right, seven examples). Results
shown are based on sequencing of the transgenic DMPK
exon-15 gene region of these clones. Sizes of residual
(CTG,CAG)n repeats and sequences flanking the de-
letions are indicated. Gray rectangles with dotted outlines
indicate that no sequence data were available for that
particular region.
Molecular TherapySmall-pool PCR, carried out on genomic DNA from these batches
of CRISPR-2- or CRISP-3-transfected cells, corroborated this obser-
vation and again demonstrated that repeat tracts were primarily
lost from the transgenic chromosome that carried the larger
(CTG,CAG)570/610 repeat tract (Figure 3). Sequence determination
across the newly formed junctions within DMPK exon 15 conﬁrmed
that healing of the initial DSB induced formation of large gaps across
the entire repeat (Figures 4B and S3). The application of single
CRISPR cleavage adjacent to the repeat may thus have utility in gener-
ating isogenic cell lines with variable (CTG,CAG)n repeat sizes.
To our knowledge, such frequent occurrence of exceptionally large
deletions has never been reported before in genome-editing studies
with endonucleases. Formation of small indels is commonly seen at
CRISPR/Cas9-induced DSBs, but deletions in the kbp size range,
preferentially formed in the unidirectional direction as we show
here, seem exceptional (e.g., compare deep-sequencing assessment
of indels after NHEJ and HDR events45). Instability resulting in
contraction has been reported for transcription activator-like
effector-based nuclease (TALEN)-cleaved short (CAG,CTG)30–7530 Molecular Therapy Vol. 25 No 1 January 2017repeats engineered in yeast46 and zinc ﬁnger nuclease (ZFN)-cleaved
(CAG,CTG)23–95 repeats engineered in human cells.47 Both studies
demonstrated that introduction of one DSB and the subsequent
recruitment of DSB repair machinery signiﬁcantly contributed to
repeat instability, mostly contraction, via mechanisms in which intra-
molecular repair reactions prevail. Repair, in which gene conversion
events between allelic segments or sister chromosomes in the S or G2
phase, could also have played a role at low frequency. Finally, as a last
speculative possibility, aberrant pairing between the extremely GC-
rich regions upstream and downstream of the repeat may have
occurred upon single cleavage, and mechanisms that promote
removal of large DNA overhangs (including the repeat!) in the single
strand annealing pathway for closure of dsDNA breaks might have
become active.48 Interestingly, contraction of the (CGG,CCG)n
repeat in the FMR1 gene occurred at a low frequency in induced
pluripotent stem cells (iPSCs) derived from fragile X-syndrome pa-
tients when cleaved upstream by CRISPR/Cas9,49 and deletion of a
(TG,CA)70 dinucleotide repeat was induced by TALEN cleavage
129 bp downstream of the repeat in zebraﬁsh.50 Extensive DNA
loss may thus be a common process if simple tandem repeats are
www.moleculartherapy.orgexposed to the DNA repair machinery by nearby DSBs. Precise com-
parison between the extent of DNA loss in the different systems re-
mains difﬁcult, however, because PCR primers used for analysis
were differentially positioned at variable distances from the
CRISPR/Cas9 or TALEN cut sites and large deletions may have
been missed in some studies.
Strikingly, the gaps that were formed across the repeat in the trans-
genic DM1 locus in DM500 cells extended to different nucleotide
positions within the repeat or its unique ﬂanking sequences. Because
remaining (CTG,CAG)n repeats (n > 50) were difﬁcult to amplify
and sequence, an exact repeat number could not be precisely deter-
mined for most products, but a rough estimate from agarose gel elec-
trophoresis indicated that considerable size contractions must have
occurred, with some alleles collapsing to less than 100 triplets. In a
few clones, we found, by sequencing, a deletion of the larger internal
part of the CTG repeat, but a fully intact ﬂanking region between the
leftover of the repeat and the actual site of CRISPR cleavage (Fig-
ure 4B). Most likely, this type of complex genome repair must
have occurred after cleavage and unidirectional trimming across
the repeat segment. We propose that the unique 11-bp (for
CRISPR-2) or 51-bp (for CRISPR-3) ﬂanking region was thereby
lost initially. Subsequently, exchange of genetic information by
gene conversion between the two (essentially) identical transgenic
chromosomes in the tetraploid DM500 cells may have served to
restore the unique ﬂanking region. Apparently, this reconstruction
leads to incomplete repair because the repeat tract itself did not serve
as a template. Direct and indirect in vitro and in vivo studies revealed
that the expanded DM1 (CTG,CAG)n repeat can adopt unusual
non-B DNA slipped strand structures.51,52 It is thus tempting to
speculate that the large deletions are facilitated by slipped strand
structures already present and/or the formation of slipped strand
structures during DSB processing. Occurrence of abnormal non-B
DNA topology may also partly explain why CRISPRs designed to
cleave inside or very close to the repeat did not work or worked
less efﬁciently (e.g., CRISPR-5 and -7; Table S1). Interestingly,
work with ZFN nucleases that cleave within the (CAG,CTG)n
repeat suggested higher efﬁciency of cleavage with increasing repeat
length.47 Further study is thus required to further determine how
chromatin conﬁguration, DNA topology, and sequence context
contribute to target site accessibility and efﬁciency of different types
of endonucleases.
Excision of a Long Expanded Repeat in DM1 Patient Myoblasts
Together, our ﬁndings demonstrate that gene editing with single
CRISPR cleavage near the trinucleotide repeat may trigger uncontrol-
lable repeat loss. Dual CRISPR/Cas9-directed cleavage may therefore
be the preferred approach for repeat deletion in DM1 patient cells. To
assess this idea in a more direct manner, we tested the mode and
efﬁciency of removal of a large expanded (CTG,CAG)n repeat
in cells with a fully authentic DM1 genotype in retrovirally immortal-
ized DM11 cl5 myoblasts derived from a DM1 patient35 with
(CTG,CAG)13 and (CTG,CAG)2,600 repeats. Due to the large
difference in allelic repeat size, any anomalous exchange of DNAbetween these chromosomes, during or after genome editing, can
be easily monitored with this cell line.
Dual expressionofCRISPR-2 and -3nucleases resulted in fairly efﬁcient
cleavage and loss of both the 101-bp fragment ([CTG,CAG]13 repeat
plus 62-bp ﬂanking sequences) from the normal allele as well as the
large 8-kb fragment ([CTG,CAG]2,600 plus ﬂanking sequences)
from the mutant allele. Through single-cell ﬂuorescence-activated cell
sorting (FACS and clonal propagation, we managed to derive 103
differentmyoblast clones from transfectedDM11 cells, allowing precise
analysis of editing events at the level of individual cells (Figure 5).Due to
difﬁculties with PCR ampliﬁcation across the large repeat, we had to
adapt our analysis strategy and used a combination of PCRs tomonitor
the editing fate of the expanded and normal allele in the same cell line-
age (Figures 5A–5D). In addition, Northern blot analysis was per-
formed on a few representative clones to verify PCR ﬁndings, showing
normal dosage or complete lack of allelicDMPKmRNAproducts in the
clones shown in Figure 5E. Table S3 provides an overview of genome
alterations that were observed for the (CTG,CAG)13 and
(CTG,CAG)2,600 allele. Because of the above-mentioned difﬁculties
with sequencing, small changes in the (CTG,CAG)2,600 allele could
not be detected. Altogether, in 36 myoblast clones (out of 103) the
CRISPR-2/-3 segment was cleanly removed from both DMPK alleles
(Figure 5F). Only one myoblast line had a deleted expanded repeat
segment and a (CTG,CAG)13 allele that was still fully intact. Alto-
gether, 69% of the (CTG,CAG)13 alleles had lost the CRISPR-2/-3
fragment cleanly (62%) or with small imperfections (7%), while 51%
of the (CTG,CAG)2,600 alleles had a deletion of the entire repeat
segment (46% clean and 5% imperfect deletions). Together, these re-
sults corroborate ﬁndings with (CTG,CAG)540/570/610 repeats in
DM500 cells and demonstrate that even repeats of the largest size class,
associated with severe DM1 forms, can be efﬁciently excised from the
DMPK gene by dual CRISPR-2/-3 cleavage. The ﬁnding that not
much difference in excision efﬁciency is observed between wild-type
(WT) and long-expandedDMPK alleles is important because it implies
that CRISPR-mediated gene editing cannot be easily tuned for selective
removal of the repeat segment from the mutant allele only unless com-
bined with clonal selection of cells with the desired targeted change to
their genome.
Unexpectedly, we detected three cell clones in which inversion of the
101 bp (CTG,CAG)13 segment had occurred (Figure S4). Inversion
can only be explained if the fragment that was liberated by dual
CRISPR activity was re-incorporated during repair of the DSB. One
idea that may explain the relatively high frequency with which we
found chromosomal fragment inversion with the (CTG,CAG)13
repeat is that the rearrangements are effectively controlled mechanis-
tically by genomic proximity and nuclear organization by a process
that keeps the ends of fragments formed by DSBs together in nuclear
locales for DNA repair.53–56 Also, others noticed a high incidence of
chromosome segment inversion upon use of dual CRISPR genome
cleavage.57 Although no evidence was found for inversion of the
(CTG,CAG)2,600 repeat, our combined observations and the results
of others make clear that careful analysis is essential and caution isMolecular Therapy Vol. 25 No 1 January 2017 31
Figure 5. Dual Genome Editing of DM11 cells Using
CRISPR-2 and -3
(A) PCR strategy used for characterization of DM11 clones
treated with CRISPR-2 and -3. Four possible outcomes for
PCR analysis are displayed (primer positions indicated on
top). Because it is not possible to amplify the (CTG,CAG)
2,600 repeat efficiently, the putative 8 kbp signal (gray
band with dotted outlines) will not be visible on gel. (B)
Results from the PCR for untreated DM11 cells and seven
independent DM11 clones treated with CRISPR-2 and -3.
Sequencing showed that the deletion of the (CTG$CAG)
2,600 repeat in clone DM11-1E6 started 15 bp upstream
of the CR-2 site and extended until 16 bp downstream of
the CR-3 site; hence, the lower signal is somewhat smaller
than the expected 559 bp (outcome 3 in A). A small dele-
tion of 11 nt was found in the (CTG,CAG)13 allele. (C and
D) Analysis of the fate of the (CTG,CAG)2,600 repeat in five
different DM11 clones that yielded a single PCR fragment
of 559 bp with the assay described in (A). A clean deletion
of the (CTG,CAG)13 repeat was confirmed by sequencing
for all five clones. To verify the fate of the (CTG,CAG)2,600
repeat, PCRs were done across the CRISPR-2 site and
across the CRISPR-3 site. Absence of products in both
reactions indicate deletions of the (CTG,CAG)2,600 repeat
in both alleles (outcome 4 in A; clones DM11-3B11 and
DM11-4A3). (E) Northern blot analysis of RNA isolated from
DM11 clones using a 32P-labeled (CAG)9 probe to verify
DMPK (CUG)2600 expression. RNA from non-treated
DM11 cells was included as positive control. Absence of
signal in clones DM11-3B11-D/D and DM11-4A3-D/D
corroborates successful repeat removal. Clone DM11-4F9
shows a slightly larger DMPK transcript than that of DM11
cells, presumably due to expansion of the repeat during
cell culture. (F) Sequence verification of excision of the
repeat-containing segment in clone DM11-4A3-D/D. Top:
DMPK exon 15 sequence that has lost the repeat-con-
taining segment aligned with the normal DMPK sequence.
Bottom: DNA sequencing profile of the DMPK exon 15
region. The site at which the two DSBs are fused is indi-
cated by an arrowhead. Absence of double peaks in-
dicates that no differences exist between the two modified
alleles.
Molecular Therapywarranted in the use of the CRISPR/Cas9 system in myoblast genome
engineering.
We expect that further adaptation of the editing strategy, for example,
by combining dual CRISPR/Cas9 cleavage with HDR to achieve
repair of genome-editing scars in the mutant DMPK gene will not
be of much help to avoid unwanted genome changes. In theory, repair
of a CRISPR-induced gap or a small inversion would be possible by
performing a second round of gene editing with CRISPR cleavage
at the junction site(s) and co-transfection of a donor fragment derived
from DMPK exon 15, for example, a single-stranded oligonucleo-
tide45 with a normal (CTG,CAG)5 repeat. Insertional recombination
of this donor fragment by HDR would leave no or only minor
sequence alterations around the CRISPR-2 and -3 recognition sites.58
Genome editing with this two-step approach is, however, only real-
istic for use in cells in vitro and too elaborate for use in vivo. Any32 Molecular Therapy Vol. 25 No 1 January 2017direct use of a donor fragment for HDR in muscle cells would
make the procedure too highly dependent on correct timing of
CRISPR/Cas9 treatment because NHEJ is a much faster process
and HDR only occurs in the S and G2-M phases.59–61 Further sophis-
tication may thus only be possible by genetic or pharmacological sup-
pression of NHEJ62,63 or by increasing HDR via use of special engi-
neered Cas9 variants,64 cell-cycle manipulation of the host cell, or
precise timing of CRISPR cleavage events. We thus anticipate that
clean-cut repair of repeat anomalies may not be easily achievable
because too many variables must be tailored for use in DM1 muscle
cells in vitro and certainly in vivo.
Biological Effects of (CTG,CAG)n Repeat Excision: Are
Biologically Relevant Sequences Lost?
Excision of the (CTG,CAG)n repeat and ﬂanking regions in DMPK
exon 15 can only have meaningful medical applications or provide
Figure 6. Effects of (CTG,CAG)n Repeat Excision on
Expression of RNA and Protein Products from
Genes in the DM1 Locus
(A and B) RNA was isolated from (A) LHCN myoblasts
(MBs) or LHCN- D=D derivatives (see Table S4 for ge-
notype specification) or myotubes (MTs) formed thereof
after 5 days in differentiation medium or (B) from DM11
and CRISPR-edited derivative (see Table S4) MBs and
MTs, and used for RT-qPCR analysis of expression of
DMPK (black bars) and SIX5 (white bars). Bar heights in
the diagram correspond to steady-state expression levels
given in arbitrary units (n = 3; mean + SEM). (C) RT-PCR
analysis of DM1-AS expression in myoblasts (signal
strength of the specific 150-bp product is given in arbi-
trary units underneath; the lower band seen in all lanes
represents a primer-dimer signal). (D) RT-PCR analysis of
major splice isoforms of DMPK mRNA formed by alter-
native skipping of exon 13 to 14 or 14 regions in DMPK
heterogeneous nuclear RNA (hnRNA) from myoblasts. (E)
Visualization of DMPK protein production in parental and
gene-edited LHCNmyotubes (5 days of differentiation) by
western blot analysis. Themost abundant DMPK isoform,
i.e., the protein produced from the longest RNA splice
isoform with exons 13 to 14 included, has an apparent
molecular weight of 80–85 kDa (arrow) and is present in all
cells. The smaller DMPK isoform, lacking exon 13 to 14
sequences, comigrates with cross-reacting proteins.80
Variation in signal strength of immunostaining with poly-
valent rabbit anti-DMPK antiserum (red) is given in arbi-
trary units below. Staining with monoclonal mouse-anti-b
tubulin antibody (green) was used as control for loading
and normalization.
www.moleculartherapy.orgtherapeutic beneﬁt if the loss of this gene segment has no adverse bio-
logical effects. To gain insight into possible side effects of our excision
strategy, we performed a bioinformatics search using RegRNA 2.0, an
integrated web server for the identiﬁcation of regulatory motifs and
elements in RNA.65 Analysis of a somewhat larger region than the
lost segment of the DMPK RNA (nucleotides 45,770,337-45,770,127
in DMPK) revealed a binding motif for IKAROS family zinc ﬁnger
3 (IKZF3), which is involved in chromatin remodeling.66 However,
IKZF3 is expressed most strongly in leukocytes, the spleen, and the
thymus, and is virtually absent in other tissues (http://www.
proteinatlas.org). In addition, two overlapping DNA motifs for poly
ADP ribose polymerase (PARP) binding and an activating transcrip-
tion factor (ATF)/cAMP response element-binding protein (CREB)
activator motif were identiﬁed. Because none of these proteins has a
known function in the DM1 locus, this leaves the role of the deleted
tract still enigmatic. A search across the novel junction sequence
generated by repair of the DSB in the edited DMPK gene yielded
no evidence for newly formed regulatory motifs.
Effects of (CTG,CAG)n Repeat Excision on Gene Expression,
DMPK mRNA Localization, and Ribonuclear Foci
We next endeavored to test the consequences of repeat deletion for
DNA coding capacity, RNA fate, integrity of cellular functions, andmyogenic capacity. Deletion of the (CTG,CAG)n repeat and 62 bp
of ﬂanking regions appeared to have no impact on DMPK’s coding
capacity or on that from its neighbor SIX5. RT-qPCR determination
of steady-state levels of DMPK mRNA in healthy control LHCN
myoblasts and gene-edited LHCN-E2.3-D/D and LHCN-B2.2-D/D
derivatives or myotubes derived thereof (Figure 6A; Table S4 for clone
designations) showed that expression did vary, but with a marginal
statistical signiﬁcance between pairs of cells in the series. Differences
could also not be attributed to the absence or presence of the repeat
tract. A similar picture was observed for DMPK mRNA expression
in gene-edited myoblasts and myotubes from the DM11 series (Fig-
ure 6B). Note that variation in expression in Figures 6A and 6B is
within the 1–2.5 arbitrary unit range when normalized to expression
levels of DMPK in the parental LHCN and DM11 myoblast or myo-
tube populations. Differences in the extent of myogenic differentia-
tion, which can be attributed to clonal (epigenetic?) inequality and
difﬁculty in precisely controlling the onset of myogenesis in culture,
may explain this variation. An overall similar picture was obtained
for expression from SIX5, the neighboring gene in the DM1 locus,
although RT-qPCR quantiﬁcation revealed that expression of this
gene in myoblasts-myotubes in culture is very low, corroborating
literature data.24,25,33 Muscle cells may thus not be the proper cell
type to assess cis-acting repeat effects on transcriptional activity ofMolecular Therapy Vol. 25 No 1 January 2017 33
Molecular TherapySIX5 because its promoter may already be in a heterochromatic
repressed state in these cells. From our ﬁndings in LHCN and
DM11 clonal derivatives, we can conclude, however, that SIX5
expression by promoter leakage is not altered upon deletion of
DMPK’s repeat tract. Further study of epigenetic effects of repeat
loss on SIX5 expression must await gene-editing efforts in cells of
other tissue origin because this is not reliably possible in our isogenic
LHCN or DM11 cell series.
Because the DNA segment comprising exon 15 of the DMPK gene is
also transcribed as part of the antisense gene in the DM1 locus
(DM1-AS)6 (A.E.E.G. Gudde, S.J. van Heeringen, A. de Oude,
I.D.G.v.K., J. Estabrook, E.T. Wang, B.W., and D.G.W., unpublished
data), we wondered whether DM1-AS expression might be affected
by loss of the (CTG,CAG)n repeat segment. We therefore moni-
tored untreated and edited LHCN myoblasts for expression of
DM1-AS RNA using semiquantitative RT-PCR (due to the high
GC content of the DM1-AS gene, reliable primer pairs for use in
qPCR could not be designed [A.E.E.G. Gudde, S.J. van Heeringen,
A. de Oude, I.D.G.v.K., J. Estabrook, E.T. Wang, B.W., and
D.G.W., unpublished data]). DM1-AS RNA was detected in all cells
(Figure 6C), with only minor variation in expression level. Collec-
tively, our results demonstrate that gene expression in the DM1 lo-
cus is not substantially altered by deletion of the fragment containing
the (CTG,CAG)5 repeat.
To verify that alternative splicing involving exon 12–15 of the
DMPK transcript was not affected in cis, RT-PCR analysis across
this region was performed (Figure 6D). Comparison of PCR prod-
ucts from isoforms present in untreated and edited LHCN myo-
blasts revealed three major splice forms that have been previously
described.31,67 No signiﬁcant differences in signal ratio for these
splice forms were found, conﬁrming our expectation that alternative
splicing across the exon 12–15 region would not be overtly affected
by the deletion. Finally, western blot analysis via immunodetection
with a DMPK-speciﬁc antibody also revealed no qualitative differ-
ences in translatability between WT and gene-edited DMPK
mRNAs. As anticipated, the longest DMPK isoform product, trans-
lated from the most abundant DMPK mRNA variant with exons
12–15 included (see Figure 6D), also yielded the strongest staining
signal in lysates from LHCN myotubes with and without the 77-
bp repeat tract, with some clonal variation in intensity (Figure 6E).
Because our genetic experiments in LHCN, DM500, and DM11
myoblasts showed that successful dual CRISPR excision of normal
and long-expanded repeat tracts yields exactly identical alleles, we
may thus conclude from these combined biological results that
repeat editing leaves the normal coding capacity of genes in the
DM1 locus in myoblasts largely intact.
Concomitantly, we expected to see reversal of the abnormalities in the
location of expanded DMPK mRNA in modiﬁed DM500 and DM11
myoblasts. Transcripts from the expanded allele in DM1 patients
form stoichiometrically abnormal complexes with RNP proteins.
These complexes prevent proper nucleocytoplasmic transport or34 Molecular Therapy Vol. 25 No 1 January 2017could in fact be formed as a result of the impairment in nuclear
export.68,69 We therefore examined whether transcripts from the edi-
ted DMPK allele had regained a normal intracellular distribution,
despite partial deletion of the 30 UTR. We used cell fractionation to
follow nuclear retention and transport of mature RNA transcripts
to the cytoplasm. Genome-edited DM500myoblasts with two original
or two edited DMPK copies formed ideal substrates for comparison
because no interference of normal-sized transcripts could occur in
these cells. Consistent with our expectation, transgenic DMPK tran-
scripts that lacked the entire (CUG)570–610 repeat tract of 1.7 kb
were mainly found in the cytoplasmic fraction, whereas expanded
RNAs resided predominantly in the nuclear fraction (Figure 7A).
Similar tests in edited DM11 cells corroborated this picture (data
not shown). To address whether removal of the trinucleotide repeat
resulted in effective dissipation of abnormal RNP structures, we per-
formed ﬂuorescence in situ hybridization (FISH) and immunoﬂuo-
rescence microscopy for subcellular MBNL1 protein distribution.
Comparison of nuclear RNP foci numbers between DM500 and
DM11 myoblast clones with and without expanded repeats revealed
a complete absence of foci in edited cells (Figures 7B, 7C, and S5).
In accordance with this observation, immunodetection of MBNL1
sequestration in original DM11 cells and clone DM11-4F9 versus
clones DM11-3B11-D/D and DM11 DM11-4A3-D/D provided clear
supportive evidence for reversal of abnormal ribonuclear complex
formation. Anti-MBNL1 stained nuclear foci were no longer seen
in myoblasts without the repeat (Figure S6).
Next, we checked whether the experimental protocol of genomic en-
gineering had not jeopardized the ability of myoblasts to form
multinuclear myotubes. Panels in Figures 8A (second row) and S7
illustrate maintenance of fusion capacity for four D/D cell lineages
(DM11-3B11-D/D, DM11-3E3-D/D, DM11-4A3-D/D, and DM11-
1E6-D/D) and one DM500 cell clone (DM500-A3.5-D2). We
consider the appearance of normal looking multinuclear myotubes
as convincing evidence for retainment of myogenic potential after
the cell manipulation and editing steps. Furthermore, more detailed
quantitative analysis revealed that loss of the DMPK repeat has a
true beneﬁcial effect because a signiﬁcant increase in fusion index
was seen for all cell clones in the D/D group compared to the
parental DM11 or CRISPR-treated myoblasts that still had a repeat.
This improvement in myogenic capacity was noticeable at both day
7 (Figures 8A and 8B) and day 10 (not shown) after onset of differ-
entiation in vitro. Thus, using our collection of isogenic human and
mouse myoblasts with and without repeats (Table S4), precise
comparative studies can now be done of all the different steps
involved in myogenic differentiation, cell-cycle arrest, activation of
the muscle-speciﬁc transcriptome, and elongation, alignment, and
fusion of myoblasts into multinucleated myotubes. Finally, removal
of the repeat also lead to normalization of alternative splicing of
biomarker RNAs in D/D myoblasts, with reappearance of adult
splice modes for both BIN-1 and DMD pre-mRNAs, as seen in con-
trol KM155 myoblasts, but different from the anomalous embryonal
splicing that occurred in the parental DM11 myoblasts and in
DM11-4F9 cells with the repeat (Figure 8C).
Figure 7. Effects of (CTG$CAG)n Repeat Excision on Nuclear DMPK RNA Retention in DM500 Myoblasts
(A) Cell fractionation was used to collect nuclear and cytoplasmic RNA from three DM500 clonal cell lines containing unmodified (CTG,CAG)540/570/610 repeats and three
independent DM500-D2 clonal cell lines with deletions of the repeat in both transgenic alleles. RT-qPCR analysis was used to determine expression levels for (1) nuclear
markers Malat1 and pre-DMPK mRNA (exon 2-intron 2 amplicon), (2) cytoplasmic markers Actb and Dmpk from mouse, and (3) mature DMPK mRNA from the human
transgene (exon 1-exon 2 and internal exon 15 amplicon). (B) RNA FISH on untreated DM500 cells, clone DM500-A2.4, containing two expanded (CTG$CAG)540/570/610
repeats, and two DM500-D2 clones. Foci containing DMPK (CUG)540/570/610 RNA were labeled using a (CAG)6-TYE563 LNA probe (red). Nuclei were stained with DAPI
(blue). No foci were seen in the DM500-D2 clones. Scale bar, 10 mm. (C) Quantification of nuclear foci in cell lines shown in (B). Each symbol represents the number of foci in
one nucleus. Mean + SEM. ***p < 0.005.
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Figure 8. Effects of (CTG,CAG)n Repeat Excision on Myogenic Capacity and Aberrant RNA Splicing in DM11 Myoblasts
(A) Immunostaining of MHC expression (green) in DM11 cells after 7 days of differentiation. Nuclei were stained with DAPI (red). Scale bar, 100 mm. (B) Fusion index of DM11
cells after 7 days of differentiation. The fusion index was calculated as the ratio of the number of nuclei inside MHC-positive myotubes to the number of total nuclei  100.
Note the improvement of fusion index after excision of the expanded repeat. Mean +SEM. **p < 0.01. (C) Comparative RT-PCR analysis ofBIN-1 andDMD in DM11 cells after
5 days of differentiation. Typical embryonic splicing patterns (e) were reverted to the normal adult (a) modes of alternative splicing after loss of the repeat. KM155 myoblasts
were used as control cells. (n = 4, mean + SEM). **p < 0.01; ***p < 0.001.
Molecular TherapyCollectively, our comparisonbetween edited andnon-editedmyoblasts
validates the already well-known detrimental inﬂuence that repeat
expansion has on DMPK RNA location and some of the best known
gain-of-function properties. More opportunities for fundamental dis-
coveries with DM1 cells emerge now. Genome-editing approaches
with selective use of single or dual CRISPR cleavage in DMPK’s 30
UTR region, perhaps in combination with a second round of editing
with HDR,58 could be applied to generate isogenic populations of
myoblasts or other DM1-relevant cell types. Simple identiﬁcation36 Molecular Therapy Vol. 25 No 1 January 2017and cloning of cells with stepwise incremental repeat lengths or repeat
sequence alterations from these populations could help to establish a
series of next-generation isogenic DM1 cell models, without the
modiﬁer effects of genetic background heterogeneity.
The outcome of our genome editing efforts demonstrates that thera-
peutic reversal of DM1-related problems is a realistic goal and may be
effectively achieved in the future. Deletion of the (CTG,CAG)n
repeat and small ﬂanking segments from the non-coding region of
www.moleculartherapy.orgthe DMPK gene had no overt consequences for in vitro cultured cells.
Better tests for capacity in myogenic development and for muscle
function still need to be done before editing can be evaluated for
use in vivo. Our dual CRISPR editing approach may thus have value
for future development of somatic gene therapy for DM1, either
directly in muscles in adult tissues in vivo, in myoﬁbers or satellite
cells, or via use in stem cells prior to muscle regeneration. An alterna-
tive genome-editing strategy with therapeutic potential, based on the
introduction of a premature poly(A) addition site a few kbps up-
stream of the repeat in the DMPK gene in iPSCs, was published by
Xia et al.70 Clearly this approach was similarly aimed at loss of repeat
toxicity at the RNA level. However, in addition to the requirement of a
repair template and activity of HDR, this modiﬁcation also invoked
greater changes in the 30 UTR of the DMPK mRNA and would not
be expected to directly correct any epigenetic abnormalities across
the mutant DM1 locus. A future comparison between the effective-
ness and adverse biological consequences of both strategies is there-
fore warranted.
Testing these CRISPR/Cas9 approaches in animal models is still very
much dependent on procedural progress at the cell level. Further im-
provements that need to be established consist of combined use of
new high-ﬁdelity Cas9 variants,37 with gene sizes that can be easily
accommodated in recombinant vectors for in vivo transduction like
AAV.71 Also, attention is needed to further improve the speciﬁcity
of gRNA recognition by using special gRNA lengths in order to
keep the off-target activity at the lowest possible level.72 Fortunately,
developments that are relevant for these issues appear with revolu-
tionary speed in the CRISPR/Cas9 ﬁeld. Our analyses provide evi-
dence that unilateral cleavage with CRISPR nucleases to only one
side of an unstable repeat in the genome should probably be avoided.
Deployment of intrinsic machinery for DNA end resection, NHEJ,
and recombination repair may produce unpredictable genome
changes across the site of cleavage and DNA closure if repeat DNA
with intrinsically odd topology hangs around as a loose end. Repair
functions from specialized endonuclease complexes (CtBP-CtIP-
MRN proteins) for resection processing may thereby fulﬁll a modula-
tory role.73 The scheme in Figure S8 provides a simpliﬁed model and
hypothetical explanation for the fate of DNA, with non-B structure
exposed by unilateral DSBs. Our work therefore includes a cautionary
note for all attempts to remove unstable DNA by genome editing in
repeat expansion disorders.
MATERIALS AND METHODS
Design and Construction of Components for the CRISPR/Cas9
Platform
A human codon-optimized version of the Streptococcus pyogenes
Cas9 protein was used in combination with a custom guide RNA.74
Throughout the text, the term CRISPR-x is used to indicate the
Cas9/gRNA ribonucleprotein endonuclease complex. Target sites
for CRISPR/Cas9 across the trinucleotide repeat in exon 15 of
DMPK (NCBI, Gene Database, GeneID: 1760, nucleotides
45,770,345–45,770,148) were selected using four CRISPR gRNA
design web tools (http://omictools.com, http://crispr.mit.edu,https://chopchop.rc.fas.harvard.edu, and https://www.dna20.com).
Different target sites were scored based on the number of predicted
off-targets and whether off-targets were perfect hits or contained
mismatches. Also, considerations like location of the target site in
the gene, GC content, and presence of a guanine at position 20 in
the target site, which appears to improve the cutting rate,75 were
included. Only CRISPR target sites with the highest scores and with
a location as close as possible (either 50 or 30 ﬂanking) to the
(CTG,CAG)n repeat were chosen. Target sites should perfectly
match the PAM sequence and 8–12 nt sequence at the 30 end of the
gRNA; mismatches at the 50 end will be tolerated.74,76,77 According
to the rules outlined by Mali et al.,74 potential off-targets were found
by identifying exact matches to the thirteen 30-most bases of the
gRNA and the PAM sequence in the human genome using BLAST
searches. The best matches were reported as potential off-target sites
for the CRISPR gRNAs.
Complementary DNA oligonucleotides specifying the 20-nt gRNA
sequence were annealed and incorporated into gRNA cloning vector
41824 (Addgene) by use of the Gibson Assembly kit (NEB). Proper
insertion of the target sequence into the vector was veriﬁed by
sequencing. The vector encoding hCas9 was obtained from Addgene
(plasmid 41815). Plasmid pMAX-EGFP encoding GFP, an indicator
of efﬁciency of transient transfection, was purchased from Lonza.
Cell Culture and Nucleofection
Immortalized human myoblasts LHCN-M2 (LHCN in short)35
and KM155C2578 were derived from primary myoblasts obtained
from control individuals unaffected with DM1 and with two
normal-sized DMPK alleles, (CTG5/CTG5) and (CTG5/CTG14),
respectively. Immortalized human DM1 myoblasts, DM11 cl5
(CTG13/CTG2600) (DM11 in short), were derived from primary
myoblasts obtained from a DM1 patient. LHCN and KM155C25
myoblasts were propagated in Skeletal Muscle Cell Growth Medium
(PromoCell) supplemented with 15% (v/v) FBS (Sigma-Aldrich) and
glutamax (GIBCO) on dishes coated with 0.1% gelatin (Sigma-Al-
drich). DM11 myoblasts were grown in a 1:1 mix of Skeletal Muscle
Cell Growth Medium and F-10 Nutrient Mix (GIBCO), supple-
mented with 20% (v/v) FBS (Sigma). Differentiation to myotubes
(fused myoblasts withR2 nuclei) was induced by growing myoblasts
to conﬂuency and replacing the proliferation medium by differentia-
tion medium consisting of DMEM (GIBCO) supplemented with
4 mM L-glutamine (GIBCO), 1 mM pyruvate (Sigma), 10 mg/mL in-
sulin (Sigma), and 100 mg/mL apo-transferrin (Sigma). All culturing
of human myoblasts was performed under normal conditions by in-
cubation under a 7.5% CO2 atmosphere at 37C.
DM500 cells, an SV40-TAgts-immortalized DM1 model myoblast
cell line expressing a transgenic human DM1 locus bearing a
(CTG,CAG)500 repeat,31 were grown in DMEM supplemented
with 4 mM L-glutamine, 1 mM pyruvate (Sigma), 20% (v/v) FBS
(PAA Laboratories), 20 units of g-IFN/mL (BD Biosciences), and
2% (v/v) chicken embryo extract (Sera Laboratories International)
on gelatin-coated dishes at 7.5% CO2 and at a permissive temperatureMolecular Therapy Vol. 25 No 1 January 2017 37
Molecular Therapyof 33C. Differentiation to myotubes was induced by growing the
myoblasts to conﬂuency on matrigel (BD) coated dishes, replacing
the proliferation medium by differentiation medium containing
DMEM (GIBCO) supplemented with 4 mM L-glutamine (GIBCO),
1 mM pyruvate (Sigma), and 5% horse serum (GIBCO), and placing
the cells at a temperature of 39C (to inactivate the SV40TAgts) in an
atmosphere of 7.5% CO2.
Expression vectors were introduced by nucleofection because this
turned out to be the most efﬁcient procedure for DNA delivery into
these difﬁcult to transfect cell types. Nucleofection was performed us-
ing the Amaxa P5 Primary Cell 4D-Nucleofector Kit (Lonza), accord-
ing to the manufacturer’s protocol for human skeletal muscle myo-
blasts. For co-nucleofection of 1  106 cells, 10 mg of hCas9 plasmid,
10 mg total of gRNA plasmid, and 2 mg of pMAX EGFP (a reporter
for transfection efﬁciency) were used. After nucleofection of LHCN
and DM500 cells and subsequent cell sorting (BD FACS Aria Cell
Sorter) for GFP-positive cells 2 days post-nucleofection, cells were
diluted to about 200 cells/mL, seeded into 96-well plates (20 cells
per well), and propagated for 11 days. DNA from these cell populations
was then isolated and analyzed by PCR. Independent LHCN cell clones
were obtained by limiting dilution cloning, and ring cloning was used
to obtain independent DM500 lines. For further analyses, each clone
was expanded to a population of 3.8  105 cells for both cell lines.
In the case of DM11myoblasts, GFP-positive cells were collected after
nucleofection by single-cell sorting 2 days post-nucleofection. Single
cells were collected in 96-well plates and cultured in medium consist-
ing of a 1:1mix of normal and conditionedmedium. Conditionedme-
dium was harvested from untreated DM11 cells that had been grown
in this medium for 3 days. Conditioned medium was ﬁlter sterilized
before use. Once the cells in the 96-well plate had reached 70% con-
ﬂuency (several weeks, no passaging), medium was switched to
normal medium and then each clonal population was expanded to
about 3.8  105 cells.
PCR Amplification Analysis of Genuine and Off-Target
Genome-Editing Events
PCRs were performed using Q5 High-Fidelity DNA Polymerase
(NEB). Most loci were successfully ampliﬁed using the standard Q5
High-Fidelity DNA Polymerase protocol. PCR on the remaining
loci was performed in the presence of the GC enhancer provided by




EBF3: 50-AGACAGCATAGCAGGTCAGCAGCAG-30 and 50-AC
CCTGAGCCCATCTGGAACCCTC-30;
ALK: 50-CAATCT-GCTTTCTCCCAGTTTGACT-30 and 50-ATC
TCGTGATCCGCCCACCTT-30;
DVL1: 50-TAACGAGCACCTACTTCATT-30 and 50-CACAACA
TAATGGGCTGG-30;38 Molecular Therapy Vol. 25 No 1 January 2017DMPK e15: 50-GCCAACTCACCGCAGTCTGG-30 and 50-TCA
GCGAGTCGGAGGACGAGG-30;
CR-2 site: 50-GCCAATGACGAGTTCGGACGG-30 and 50-AGC
AGCAGCAGCATTCCCG-30;
CR-3 site: 50-CCATTTCTTTCTTTCGGCCAGGCTG-30 and 50-
GCGAGTCGGAGGACGAGGTCAATAA-30.
T7 Endonuclease I Cleavage Assay
For identiﬁcation of indels after CRISPR/Cas9 cleavage, the T7 endo-
nuclease I assay, adapted from Wyvekens et al.,36 was used. Brieﬂy,
cells were collected and digested with 100 mg/mL proteinase K in lysis
buffer (100 mMTris-HCl, pH 7.5, 5 mMEDTA, 0.2% SDS, and 2mM
NaCl) for 3 hr at 55C. Samples were centrifuged for 15 min at
16,000  g (4C). Supernatants were collected and equal volumes
of isopropanol were added, after which the samples were centrifuged
for 20 min at 16,000 g at 4C. Supernatants were discarded, and the
pellets were washed once with 200 mL of 70% ethanol. After the
washing step, the DNA pellets were dried and dissolved in TE buffer
(10 mM Tris, pH 7.5, and 1 mM EDTA).
PCR primers were designed to amplify the sequence containing the
CRISPR target site, such that the total length of the PCR product
was about 600 bp, with the cleavage site located approximately in
the middle. Pertinent segments were ampliﬁed by PCR, and the re-
sulting products were puriﬁed using a gel extraction kit (QIAGEN).
Approximately 250 ng of puriﬁed PCR product was denatured at
94C and re-annealed in NEB buffer 2 using a thermocycler
(5 min, 95C; ramp down to 85C at 2C/s; ramp down to 25C
at 0.1C/s; hold at 4C). The re-annealed PCR products were di-
gested with 10 U T7 endonuclease I (NEB) for 15 min at room tem-
perature. The reaction was stopped by adding 2 uL of 0.25 M EDTA,
and PCR products were resolved by electrophoresis on a 1% agarose
gel. DNA fragments were stained with 0.5 mg/mL ethidium bromide
(Amresco), and ImageJ software was used for quantiﬁcation of
band intensities. Targeting efﬁciencies were calculated using the
following formula: % gene modiﬁcation = 100  (1[1  fraction
cleaved]1/2).79
Small-Pool PCR
Small-pool PCR was carried out as previously described using either
DM-C and DM-DR or the more distal DM-A and DM-BR.41 PCR
conditions were 28 cycles of 96C for 45 s, 68C for 45 s, and 70C
for 3 min, followed by 68C for 1 min and 70C for 10 min. The
PCR buffer was Custom PCRMaster Mix-No Taq (Thermo Scientiﬁc
#SM-0005) supplemented with 69 mM b-mercaptoethanol (Sigma-
Aldrich). Taq polymerase (Sigma-Aldrich) was used at 1 unit per
10 mL of reaction. Template DNA from untreated and CRISPR/
Cas9-treated DM500 cells was measured using the Qubit ﬂuorometer
and the dsDNA HS kit (Thermo Fisher Scientiﬁc). 1% agarose gels
were blotted onto Hybond Nmembrane (GEHealthcare) and hybrid-
ized. Probes and molecular weight marker (1 kb+ ladder, Thermo
Fisher Scientiﬁc) were labeled using 32P-dCTP (Perkin Elmer) and
the Random Primers DNA Labeling System (Thermo Fisher
www.moleculartherapy.orgScientiﬁc). The (CTG,CAG)n repeat probe DM56 was a 244-bp frag-
ment comprising (CTG,CAG)56 and 54-bp ﬂanking sequences
ampliﬁed using primers DM-C and DM-ER (50-AAATGGTCTGT
GATCCCCCC-30) using template DNA from a late-onset DM1 pa-
tient. Probe H was a 99-bp fragment that hybridizes to the 50 ﬂanking
sequence upstream of the (CTG,CAG)n repeat. Probe H was ampli-
ﬁed using primers DM-H (50-TCTCCGCCCAGCTCCAGTCC-30)
and DM-CR (50-AGGACCCTTCGAGCCCCGTTC-30).
Karyotyping
Karyotyping was performed to conﬁrm tetraploidization of the
DM500 cell line. DM500 cells were grown to sub-conﬂuency in a
six-well dish and incubated in 1 mL of DMEM medium containing
20 mL of 10 mg/mL colcemid (GIBCO) for 2 hr at 37C. Cells were
trypsinized and collected by centrifugation. The cell pellet was resus-
pended in 1 mL of 75 mM KCl, after which another 2 mL of 75 mM
KCl was added to the sample. Cells were incubated for 10min at 37C.
Three drops of ﬁxative solution (75%methanol and 25% glacial acetic
acid) were added to the sample, and cells were collected by centrifu-
gation. The pellet was washed twice with ﬁxative solution and resus-
pended in 6–20 drops of ﬁxative solution, depending on the amount
of cells. Drops of cell suspensions were dropped from a height of
30 cm onto clean wet slides and left to dry. The cells were then stained
using freshly made Giemsa Stain solution (Merck). Chromosomes
were analyzed using a phase contrast microscope with a 40
objective.
Southern Blot Hybridization of PCR Products
To determine the presence of the (CTG,CAG)500 repeat in CRISPR/
Cas9 genome-edited DM500 myoblasts, we used PCR ampliﬁcation
of the (CTG,CAG)500 repeat-containing gene segment, followed
by Southern blot hybridization. PCR products were resolved by elec-
trophoresis on a 1% agarose gel, transferred by capillary transfer to a
Hybond-XL nylon membrane (Amersham Pharmacia Biotech), and
hybridized with 32P-labeled oligonucleotides. A DMPK oligo (50-
AGAACTGTCTTCGACTCCGGG-30), located 50 of the CRISPR
cleavage sites, was used to visualize PCR products from both the un-
modiﬁed DMPK gene and from cells with a deletion of the region be-
tween the two CRISPR sites. The oligo was 50 end labeled using ɣ32P-
ATP and T4 polynucleotide kinase and hybridized to the membrane
in Church-Gilbert hybridization solution overnight at 42C. The
membrane was washed, exposed to a Bio-Rad Phosphor Imaging
Screen, and imaged by Phosphor-Imager analysis (Molecular Imager
FX, Bio-Rad). Analysis was performed with Quantity One (Bio-Rad)
and ImageJ software. After imaging, the probe was stripped from the
membrane using boiling buffer (0.1 X SSC and 0.1% SDS). Subse-
quently, using similar conditions for hybridization, washing, and
exposure analysis, 32P-end-labeled (CAG)9 probe was used to visu-
alize PCR products containing an expanded (CTG,CAG)n repeat.
Western Blot Analysis of DMPK
Analysis of DMPK protein production in myoblasts was performed
by western blotting, essentially as described by Oude Ophuis et al.80
Staining with monoclonal anti-b tubulin E7 antibody (Develop-mental Studies, Hybridoma Bank, University of Iowa) was used as
control for loading. As secondary antibodies, 1:10,000 goat-anti-
mouse 800CW and goat-anti-rabbit 680RD (Thermo Fisher) were
used. Detection was performed on the Odyssey CLx InfraredWestern
Blot Imaging System (Westburg). ImageJ software was used for quan-
titative protein expression analysis.
Cellular Fractionation and RNA Isolation
The protocol for RNA isolation from different cell fractions was
adapted from Rio et al.81 Brieﬂy, 0.6  106 cells (70% conﬂuency)
were trypsinized and collected by centrifugation. Cell pellets were
washed twice with cold PBS, after which the cell pellet was resus-
pended in 0.5 mL of ice-cold cell disruption buffer (20 mM Tris-
HCl [pH 7.5], 1.5 mM MgCl2, 10 mM KCl, and 10 mM dithiothrei-
tol). After 10 min in cell disruption buffer on ice, the cells were
transferred to a 1-mL glass Dounce Tissue Grinder (Wheaton) and
homogenized using 15 strokes with a tight pestle. The crude cell lysate
was transferred to a fresh tube and 5 mL of 10% Triton X-100 (Sigma-
Aldrich) was added to a ﬁnal concentration of 0.1% Triton X-100 and
mixed by inversion ﬁve times. Cell nuclei were pelleted immediately
by centrifuging the homogenate at 1,500  g at 4C for 5 min. The
supernatant containing the cytoplasmic fractions was collected.
RNA was isolated from both fractions using the Aurum Total RNA
Mini Kit (Bio-Rad) according to the manufacturer’s protocol. All
RNA preparations were quantiﬁed using a NanoVue spectrometer
(GE Healthcare Europe). Approximately 500 ng of RNA of the cyto-
plasmic fractions and equal volumes of the corresponding nuclear
fractions were used as a template for subsequent cDNA synthesis
and RT-qPCR.
Northern Blotting
To determine the absence or presence of (CUG)n-repeat-containing
RNA transcripts from the (CTG)13 and (CTG)2600 alleles in
CRISPR/Cas9 genome-edited DM11 myoblasts, Northern blotting
was performed according to standard procedures. RNA was isolated
from the DM11 cell clones using an Aurum Total RNA Mini Kit.
All RNA preparations were quantiﬁed using a NanoVue spectrom-
eter. Depending on the RNA yield from different clonally expanded
cell lineages, 5–10 mg of RNA was dissolved in loading buffer and
loaded onto a 1.2% agarose-formaldehyde denaturing gel and
resolved by electrophoresis. RNA was transferred to Hybond-XL
nylon membrane by capillary transfer in 10X SSC and UV cross-
linked using a UV Stratalinker 1800 (Invitrogen). The membrane
was hybridized with a 32P-end-labeled (CAG)9 probe in Church-
Gilbert hybridization solution overnight at 42C, after which the
membrane was washed and the probes were detected and analyzed
as described above.
RNA FISH and Image Analysis of Ribonuclear Foci
DM500 cells were grown in eight-well IBIDI chambers coated with
0.1% gelatin (Sigma) and expanded to 90% conﬂuency. DM11 cells
were grown on coverslips coated with 0.1% gelatin (Sigma-Aldrich)
to 50%–60% conﬂuency. The cells were washed once with PBS and
ﬁxed in 4% formaldehyde, 5 mM MgCl2 in PBS for 10 min at roomMolecular Therapy Vol. 25 No 1 January 2017 39
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after which ice-cold 70% ethanol was added for overnight incubation.
The ice-cold 70% ethanol was refreshed once, after which the
ﬁxed cells were washed two times for 5 min with PBS at room temper-
ature. Cell-containing coverslips were prehybridized in 40% deion-
ized formamide (Ambion) in 2X SSC (Ambion) for 20 min at room
temperature, followed by overnight hybridization at 37C with
0.1 ng/mL (CAG)6-TYE563 LNA probe (Exiqon) in hybridization
buffer containing 40% deionized formamide, 2 mg/mL BSA (Sigma),
100 mg/mL dextran sulfate (Pharmacia), 0.1% Triton X-100 (Sigma-
Aldrich), 1 mg/mL herring sperm DNA (Promega), 100 mg/mL yeast
tRNA (Ambion), 2 mM vanadyl ribonucleoside complex (NEB), and
2 X SSC. Coverslips were washed twice for 5 min with PBS before
staining cell nuclei with 1 mg/mL DAPI (Sigma) in PBS for 10 min
at room temperature. Cells were then washed twice for 5 min with
PBS, and preparations were mounted with Mowiol 488 (Hoechst).
Fluorescent images were acquired using a Leica DMI6000B micro-
scope with a 63 objective in three different wavelength intervals us-
ing ﬁlter sets for DAPI, ﬂuorescein isothiocyanate (FITC), and tetra-
methylrhodamine (TRITC)/Cy3. Images were subsequently analyzed
using FIJI software. DAPI masks were created using auto-threshold-
ing using Huang’s method,82 followed by a watershed. For analysis of
DM11 cells, a “ﬁndmaxima” option in FIJI was applied for the TRITC
channel using a noise tolerance of 200, resulting in images containing
single points. Positive pixels were counted in the nucleus using the
previously made DAPI masks. For DM500, “ﬁnd maxima” was also
applied for Cy3, but using a noise tolerance of 150. Fluorescence
signal intensity needed correction for aspeciﬁc maxima by subtracting
the consistently high autoﬂuorescence background signal observed in
DM500 cells. Using the DAPI masks, the positive pixels in each nu-
cleus were counted.
RT-qPCR
To quantify endogenous RNA levels in the various cell lines, RT-
qPCR was performed. RNA was isolated using an Aurum Total
RNA Mini Kit (Bio-Rad) according to the manufacturer’s protocol.
Next, cDNA synthesis was performed using 500 ng of RNA as a tem-
plate, with random hexamers and the iScript cDNA synthesis kit (Bio-
Rad) in a total volume of 20 mL. For RT-qPCR, 3 mL of the 10-fold
diluted cDNA sample was mixed in a ﬁnal volume of 10 mL contain-
ing 5 mL of iQ SYBR Green Supermix (Bio-Rad) and 4 pmol of each
primer. Samples were analyzed using the CFX96 Real-time System
(Bio-Rad). As negative controls, no-RT controls (RT) and no-tem-
plate controls (NTCs) were included. Endogenous DMPK levels were
normalized to GAPDH and HPRT1 levels.
Primers used:Malat1: 50-GCTGTTGGCACGACACCTTC-30 and 50-
ACTGTGAACCAAAGCCGCAC-30; Actb: 50-GCTCTGGCTCCTA
GCACCAT-30 and 50-GCCACCGATCCACACAGAGT-30; Dmpk
e15(30): 50-GGATCAGCAAGACCTCTGCCAG-30 and 50-TGTGGC
TCCGTTGTTAGAGTGC-30; DMPK e1-e2: 50-ACTGGCCCAGGA
CAAGTACG-30 and 50-CCTCCTTAAGCCTCACCACG-30; DMPK
e2-in2: 50-GAGGGACGACTTCGAGATTCTGAA-30 and 50-CAC40 Molecular Therapy Vol. 25 No 1 January 2017CACGAGTCAAGTCAGGC-30; DMPK e15(30): 50-TGCCTGCTT
ACTCGGGAAATT-30 and 50-GAGCAGCGCAAGTGAGGAG-30;
GAPDH: 50-CCCGCTTCGCTCTCTGCTCC-30 and 50-CCTTCCCC
ATGGTGTCTGAGCG-30; HPRT1: 50-TGACACTGGCAAAACAA
TGCA-30 and 50-GGTCCTTTTCACCAGCAAGCT-30. Primers for
SIX5 have been described previously;33 however, because the efﬁ-
ciency of ampliﬁcation for this primer pair appeared to be an artiﬁcial
113.5% in our analyses, an efﬁciency correction was included in the
calculations.
RT-PCR Analysis of in cis and in trans Effects on Alternative
Splicing and DM1-AS RNA Expression
To analyze DMPK exon 12–15 splice isoforms, 500 ng of total RNA
was used as a template for cDNA synthesis with random hexamers us-
ing the Superscript III RT kit (Invitrogen) in a total volume of 20 mL,
according to the manufacturer’s protocol. The cDNA was diluted
1:10, and 1 mL was used for subsequent ampliﬁcation by PCR using
forward and reverse DMPK e12–e15 primers: 50-GAACCGGGACC
TAGAGGCACACGT-30 and 50-TCGGAGCGGTTGTGAACTG-30.
As negative control, a no-RT control (RT) was included. PCR
products were separated on a 1% agarose gel. Quantiﬁcation was per-
formed using ImageJ software.
For analysis of DM1-AS expression, 1 mg of total myoblast RNA was
used as a template for cDNA synthesis with 2 pmol of gene-speciﬁc
primer RT AS 3CAG 50-CGACTGGAGCACGAGGACACTGA
CGCCTGCCAGTTCACAACCGCTCCGAGCGT-30 and the Super-
script III reverse transcriptase kit (Invitrogen) in a total volume of
20 mL, according to the manufacturer’s protocol. Undiluted cDNA
(1 mL) was used for subsequent ampliﬁcation by PCR using AS
DMPK: 50-CCTTCGAGCCCCGTTCGC-30 and RT AS 3CAG
primer.83 As negative control, a no-RT control (RT) was included.
PCR products were separated on a 2% agarose gel.
To analyze BIN1 exon 11 inclusion and DMD exon 78 inclusion in
alternative RNA splicing, 500 ng of total RNA from myotubes at
5 days of differentiation was used as a template for cDNA synthesis
with random hexamers using the iScript cDNA synthesis kit (Bio-
Rad) in a total volume of 20 mL. The cDNA was diluted 1:10, and
1 mL was used for subsequent ampliﬁcation by PCR using forward
and reverse primers BIN1 ex11 50-AGAACCTCAATGATGTGC
TGG-30 and 50-TCGTGGTTGACTCTGATCTCGG-30 or DMD
ex78 50- TTAGAGGAGGTGATGGAGCA-30 and 50-GATACTAAG
GACTCCATCGC-30. As negative control, a no-RT control (RT)
was included. PCR products were separated on a 2.5% agarose gel.
Quantiﬁcation was performed using ImageJ software. Exon inclusion
was quantiﬁed as the percentage of the total intensity of isoform
signals.
Immunofluorescence Staining
For assaying myogenic capacity with myosin heavy chain (MHC)
staining, DM11 clones were seeded in eight-well IBIDI chambers,
propagated for 2 days in growth medium, and cultured in differenti-
ation medium for 5 or more days. Cells were washed with PBS and
www.moleculartherapy.orgﬁxed with 2% PFA in 0.1 M phosphate buffer for 15 min at room tem-
perature. After ﬁxation, cells were washed with PBS again and per-
meabilized with blocking buffer (0.1% Triton X-100 [Sigma-Aldrich],
0.1% glycin [Merck], and 3% BSA [Sigma] in PBS) for 30 min at room
temperature. Samples were incubated overnight at 4C with blocking
buffer containing 1:10 diluted anti-MHC antibody, MF 20 (DSHB,
University of Iowa). Cells were washed with PBS and incubated
with 4 mg/mL goat-anti-mouse AF488 (Thermo Fisher) and 100 ng/
mL DAPI (Sigma) in blocking buffer for 1 hr at room temperature
in the dark. Cells were washed and kept in PBS. Fluorescent images
were acquired using a Leica DMI6000B microscope with a 10
objective.
For visualization of co-accumulation of MBNL1 with (CUG)n
expanded DMPK transcripts in intranuclear RNP foci, DM11 cells
were grown on coverslips coated with 0.1% gelatin (Sigma-Aldrich)
to 80% conﬂuency. Cells were washed with PBS, ﬁxed in ice-cold 1:1
acetone/methanol, incubated overnight at 20C, washed with PBS
again, and incubated for 1 hr in block buffer containing 3% BSA
(Sigma), 0.1% glycin (Merck), and 0.1% Triton X-100 (Sigma) at
room temperature. Samples were then incubated overnight at 4C
in the same buffer containing 1:10 diluted anti-MBNL1 antibody,
MB1a (4A8) from DSHB, University of Iowa. Samples were washed
and incubated with 4 mg/mL goat-anti-mouse AF488 (Thermo
Fisher) and 100 ng/mL DAPI (Sigma) in blocking buffer for 1 hr
at room temperature in the dark. Finally, slides with ﬁxed cells
were washed with PBS, milliQ, 70% and 100% ethanol, and mounted
with Mowiol 488 (Hoechst). Images were acquired using an
Olympus FV 1000 microscope with a 60, NA 1.35 oil objective.
Quantiﬁcation of MBNL1 foci was performed on wide-ﬁeld images
taken with a Leica DMI600B microscope with a 63, NA 0.90 dry
objective.Statistical Analysis
All statistical analyses were performed with GraphPad Prism version
5.01 software (GraphPad Software) using one-way ANOVA or Stu-
dent’s t test. All values in graphs are presented as mean ± SEM.
The signiﬁcance level was set at 0.05. *p < 0.05; **p < 0.01; ***p <
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